Tryptophan depletion in SSRI-recovered depressed outpatients by Spillmann, M.K. et al.
Abstract Rationale: Recently, a number of studies have
challenged the finding that acute tryptophan depletion
(TD) increases depressive symptoms in medicated, for-
merly depressed patients. The present study examined
the effects of acute nutritional TD on remitted depressed
patients currently treated with selective serotonin reup-
take inhibitors. In an attempt to clarify conflicting earlier
findings, the effects of a number of clinical variables on
outcome were also investigated. Methods: Ten patients
underwent TD in a double-blind, controlled, balanced
crossover fashion. The control session followed the pro-
cedure of Krahn et al. (1996 Neuropsychopharmacology
15:325–328). Sessions were 5–8 days apart. Results: TD
was significantly related to increased scores on clinician-
rated depression and anxiety scales, and on self-rated de-
pression, anxiety, and somatic symptoms. The control
challenge had no effect, despite the fact that the reduc-
tions in plasma tryptophan during the control session
were unexpectedly high. Some evidence was found for a
threshold in the relationship between reduction of plas-
ma tryptophan and mood response. Conclusions: The
mood effect of TD in medicated, formerly depressed pa-
tients was confirmed. A threshold may exist for mood ef-
fects following TD, implying that recent negative find-
ings may have been caused by insufficient depletion. No
other predicting or mediating factors were identified, al-
though the variable “history of response pattern to medi-
cation” deserves further study.
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Introduction
The tryptophan depletion (TD) challenge is a useful
model for studying brain serotonin function. Reducing
tryptophan availability to the brain impairs serotonin
synthesis due to the dependence of CNS serotonin syn-
thesis on plasma levels of its amino acid precursor, 
tryptophan (Biggio et al. 1974; Carpenter et al. 1998).
Nutritional TD has been shown to cause depressive
symptoms in remitted depressed patients on antidepres-
sant treatment (Delgado et al. 1990; Smith et al. 1997).
The probability of a TD-induced symptom exacerbation
is highest in patients who were treated with antidepres-
sants affecting the serotonergic system [selective sero-
tonin reuptake inhibitors (SSRIs); Delgado et al. 1991,
1999]. Certain other psychiatric syndromes also seem
vulnerable to symptom exacerbation following TD 
(Van der Does 2000a).
It should be noted, however, that even in SSRI-treated
patients, TD causes clinically significant symptoms in
not more than 50–60% of patients (see Van der Does
2000a for a review). Furthermore, a number of studies
have been published in which relapse rates during TD
were much lower (Bremner et al. 1997; Aberg-Wistedt 
et al. 1998). One study (Moore et al. 1998) even found
no mood effects. Variables that have been related to re-
sponse to TD include time since remission (Moore et al.
1998) and history of suicidal tendencies (Leyton et al.
1997). However, support for these variables is weak or
inconsistent (Van der Does 2000a). The current study
further investigated possible correlates and predictors of
the effects of acute nutritional TD in remitted depressed
patients. Variables that were examined were duration of
remission of depressive symptoms, pattern of response to
antidepressant treatment (“true drug pattern” vs “placebo
pattern”), and number of previous episodes of major de-
pression.
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Materials and methods
Subjects
Eligible subjects were outpatients between the ages of 18 and
65 years with a history of major depressive disorder. At the time
of enrollment, patients had to be in remission following treatment
with an SSRI. Pretreatment diagnoses were ascertained using the
Structured Clinical Interview for DSM-IV – Patient Edition
(SCID-P; First et al. 1995). All subjects were required to have
their major depression in clinical remission and to show marked
improvement in overall functioning for at least 3 months of anti-
depressant treatment, as reported by the patient. All subjects 
were also required to have a score lower or equal to 8 on the mod-
ified 25-item Hamilton Rating Scale for Depression (HRSD-25;
Hamilton 1967). All enrolled subjects were concurrently treated
with an SSRI. During the SCID-P interview, information was
gathered about the number of prior episodes of major depression
and the type of response pattern to the SSRI (i.e., “true drug” re-
sponse when delayed and persistent vs “placebo pattern” when
early and/or a history of non-persistent response to medication).
This information was checked with the medical records.
At the time of enrollment, subjects provided written informed
consent after the nature and the procedure of the study had 
been fully explained. To rule out medical and neurological illness,
the subjects underwent complete physical examination, including
ECG and laboratory tests.
Tryptophan depletion
In order to achieve a 90% reduction of tryptophan levels, the ex-
perimental session included a 24-h low tryptophan (160 mg/day)
diet followed by a second day on which a tryptophan-free amino
acid (AA) drink along with 25 AA capsules were administered.
The AA drink contained L-alanine 5.5 g, L-phenylalanine 5.7 g, 
L-proline 12.2 g, L-lysine monohydrochloride 11.0 g, glycine
3.2 g, L-serine 6.9 gm, L-histidine 3.2 g, L-threonine 6.9 g, L-iso-
leucine 8.0 g, L-tyrosine 6.9 g, L-leucine 13.5 g, and L-valine
8.9 g. The AA drinks were prepared under the direction of a re-
search dietitian by mixing the above AA powder with water for 
a final volume of 350 ml and flavored to taste with Hershey’s
chocolate syrup. Subjects drank the solution through a straw.
Three amino acids were not included in the drink because of their
unpleasant taste and were administered in 25 capsules immediate-
ly after the drink. The capsules contained a total dosage of 10.55 g
with the following distribution of amino acids: L-methionine 3.0 g,
L-arginine 4.90 g, and L-cysteine 2.65 g.
The control session (aimed at leading to a 10–20% reduction
of tryptophan levels) followed the procedure described by Krahn
et al. (1996). A 24-h 160 mg/day tryptophan diet was followed the
next morning by a 350-ml AA drink and 25 capsules. The drink
and capsules contained the same amino acids as in the active chal-
lenge condition, but only 25% of their weight.
Behavioral ratings
Subjects were continually monitored during the day of their tests
by trained clinicians and research assistants. All raters were blind
to the sequence of testing. Behavioral ratings consisted of the mod-
ified 6-item version of the original 17-item Hamilton Rating Scale
for Depression (HRSD-6; Bech et al. 1981) and the Hamilton 
Rating Scale for Anxiety (HRSA; Hamilton 1959). The item re-
garding insomnia was excluded from the HRSA. Furthermore, the
following self-rated scales were administered: the Symptom Ques-
tionnaire (SQ; Kellner 1987) and the Anger Attacks Questionnaire
(Fava et al. 1991).
Procedure
TD was conducted in a double-blind, controlled, balanced, cross-
over fashion. On the first day of the study, subjects arrived at the
General Clinical Research Center of the Massachusetts General
Hospital after fasting overnight. Following plasma collection and
ratings, patients left the hospital with a low-tryptophan diet to take
home. The low-tryptophan diets were designed by a research dieti-
tian and were composed of regular food low in tryptophan, con-
taining 2,300 calories. During the diets, all patients consumed a
cookie which either contained 0.0003 g tryptophan (prior to the
depletion challenge) or 0.0484 g tryptophan (prior to the control
challenge).
On day 2 of the study, subjects arrived at the center after an
overnight fast for either a TD session or a control session. Ratings,
blood sampling, and vital signs were performed and this was fol-
lowed by the ingestion of the AA drink and capsules 30 min later.
Subjects remained in a private room of the center for the next 7 h
but were free to walk about the room, use the toilet, and drink wa-
ter. They continued to fast throughout the day until the test was
completed, when they returned to regular food intake.
Behavioral ratings were obtained at day 1 prior to starting the
diet, at day 2 prior to ingestion of the AA drink, as well as 5 and
7 h after ingestion. Ratings were obtained again in the morning of
day 3, when adverse events were also recorded. At all these time
points, blood samples for measurement of free and total trypto-
phan (Trp) and large neutral amino acids (LNAAs) were obtained.
Within 5–8 days after the first session, patients underwent the sec-
ond challenge, using an identical procedure. Subjects were com-
pensated up to $160.
Tryptophan measurement
Total plasma tryptophan level was measured by high-performance
liquid chromatography with fluorometric detection. Free plasma
tryptophan was assayed by obtaining the ultrafiltrate of plasma
from cellulose-based filters and subjecting the ultrafiltrate to the
high-performance liquid chromatography with fluorometric detec-
tion method.
Data analyses
A patient was considered a “responder to TD” if the increase in
HRSD-6 scores was at least 50% and at least three points. The ra-
tionale for this criterion comes from a study by O’Sullivan et al.
(1997); three points increase on the HRSD-6 is approximately half
of the difference between depressed patients before and after treat-
ment. The relationship between pattern of response and response
to TD was examined using χ2 analysis. Results from behavioral
and biochemical ratings were also analyzed by means of a two
(session: TD/control) × two (time: pre/postmeasurement) repeated
measures analysis of variance. The relationship among changes in
depression scores and biochemical measures was investigated by
calculating correlations among residualized change scores. To in-
vestigate the influence of number of episodes and duration of re-
mission, correlations were calculated between these variables and
the change in symptom scores. One case with an extreme number
of episodes (40) was a univariate outlier. For the statistical analy-
sis, this variable was recoded as 10.
Results
Description of sample, drop-outs, and side-effects
Of the 17 subjects who entered the study, 15 completed
at least one challenge test, and 10 subjects completed the
study protocol. The two patients who did not complete
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one session were one female patient whose HRSD-25
score had suddenly increased to 19 on the morning of
day 1 of the first session (control). The next morning the
score was still 13, so this subject no longer fulfilled in-
clusion criteria. One male patient had to unexpectedly
leave town before the study started. Of the remaining
five drop-outs, one female patient showed symptoms of
an anxiety attack during the first blood drawing on day 2
of the first (control) challenge. Three patients (two fe-
males) completed the first session (two depletion, one
control) but withdrew before the second session because
of the side-effects. One female patient completed the
first session and withdrew on the morning of day 2 of the
second session (control) because of side-effects. Notable
side-effects during the tests were nausea, vomiting,
headaches, diarrhea, anxiety attack prior to blood draw-
ing, hot and cold flushes, and faintness. Further sample
characteristics are listed in Table 1.
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Table 1 Sample characteristics and main results. Depression
scores refer to Hamilton Depression Rating Scale, six-item ver-
sion, scores on day 2 at 9 a.m. (Pre) and at 4 p.m. (Post), and on
day 3 at 11 a.m. (Fu). Remis. Duration of remission (months),
Epis. number of depressive episodes, Medication type and dosage
of medication, Pattern response pattern to selective serotonin re-
uptake inhibitor (SSRI), Responder fulfills criteria of responder to
tryptophan depletion (TD) challenge, ΔTRP reduction of ratio free
tryptophan/large neutral amino acids at 4 p.m. compared to 9 a.m.,
both on day 2
Baseline characteristics TD challenge Control challenge
Number Sex Age Remis. Epis. Medication Pattern Responder Depression ΔTRP Depression ΔTRP
(years) scores Post scores Post
Pre Post Fu Pre Post Fu
1 M 51 36 1 Fluoxetine 40 True Yes 2 5 1 89.6 1 0 0 17.8
2 F 55 30 1 Sertraline 100 True No 1 2 1 a 1 0 0 a
3 F 57 22 40 Fluoxetine 100 Placebo No 1 2 2 41.9 5 3 0 85.0
4 F 40 11 1 Fluoxetine 40 True Yes 0 7 3 87.9 0 1 1 29.9
5 F 29 4 5 Sertraline 200 True Yes 0 4 1 93.2 1 0 6 43.0
6 F 50 4 6 Venlafaxine 300 True Yes 4 10 11 94.3 1 3 2 79.0
7 M 40 5 2 Paroxetine 20 Placebo Yes 0 5 0 90.7 1 0 2 20.2
8 F 47 7 1 Fluoxetine 20 Placebo No 1 1 0 90.7 0 0 0 76.3
9 F 54 5 6 Paroxetine 60 True Yes 1 10 8 88.5 4 3 5 22.9
10 M 27 3 6 Fluoxetine 40 True No 1 1 2 64.1 0 0 0 12.1
Mean 45.0 6.9 12.7 1.1 4.7 2.9 82.3 1.4 1.0 1.6 42.9
SD 10.7 11.9 12.2 1.2 3.4 3.7 17.7 1.7 1.4 2.2 29.3
a Lost to data analysis because of interfering peak in sample
Table 2 Biochemical changes during TD and control challenge (n=10). Note: n=9 for free tryptophan (TRP) and free TRP/large neutral
amino acids (LNAA)
TD challenge Control challenge Significance
of the 
Day 2, Day 2, Percentage Day 2, Day 2, Percentage interaction
9 a.m. 4 p.m. change 9 a.m. 4 p.m. change term
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Total TRP (nM/ml) 32.1±7.4 10.3±7.0 –67.9±20.7 33.0±5.6 21.0±9.8 –42.0±20.3 0.074
Free TRP (nM/ml) 5.0±1.0 1.7±1.1 –67.4±18.4 5.9±2.1 3.6±1.2 –33.7±27.3 0.386
Total TRP/LNAA ratio 0.076±0.013 0.013±0.012 –82.1±18.9 0.073±0.011 0.037±0.019 –52.6±23.7 0.037
Free TRP/LNAA ratio 0.012±0.003 0.002±0.002 –82.3±17.7 0.013±0.006 0.006±0.002 –42.9±29.3 0.240
Table 3 Behavioral changes during tryptophan depletion and control challenge (n=10). HAM-D6 Hamilton Depression Rating Scale,
six-item version, HAM-A Hamilton Anxiety Rating Scale, SQ Symptom Questionnaire
TD challenge Control challenge Significance 
of the 
Day 2, 9 a.m. Day 2, 4 p.m. Difference Day 2, 9 a.m. Day 2, 4 p.m. Difference interaction 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD term
HAM-D6 1.1±1.2 4.7±3.4 3.6±3.1 1.4±1.7 1.0±1.4 –0.4±1.2 0.002
HAM-A 2.2±1.5 7.4±6.6 5.2±6.4 2.5±3.0 1.9±2.2 –0.6±3.5 0.039
SQ depression 2.5±2.5 6.7±5.1 4.2±4.4 3.8±3.7 3.2±3.0 –0.6±2.4 0.031
SQ anxiety 2.9±3.9 5.9±6.6 3.0±3.9 2.3±3.9 2.2±4.6 –0.1±1.4 0.032
SQ anger 1.3±1.4 3.1±3.7 1.8±3.6 1.5±2.3 2.5±3.4 1.0±3.7 0.502
SQ somatic 4.5±4.1 8.8±5.8 4.3±5.6 5.7±4.9 4.3±4.9 –1.4±4.6 0.011
The unexpected high reduction of tryptophan levels
during the control session prompted us to take a closer
look at the dose-response relationship between change in
mood scores and reduction of tryptophan levels. Figure 1
suggests that there is no linear or curvilinear dose-
response curve, but rather a threshold. All patients who
showed symptom changes had at least an 80% reduction
of Trp/LNAA ratio. This was examined further using re-
ceiver operating characteristic (ROC) analysis. The ROC
curve is a measure of accuracy of a diagnostic test (Metz
1978). Using our predetermined criteria of HRSD
change scores to categorize patients as “actually posi-
tive” or “actually negative”, this analysis showed that a
threshold of 88.2% reduction of free Trp/LNAA predicts
response to TD with a sensitivity of 0.84 and a specifici-
ty of 0.76. The area under the curve is 0.84 (SD=0.18).
When the data from the placebo condition are included,
sensitivity rises to 0.92, specificity to 0.82, and the area
under the curve is 0.95 (SD=0.05). It should be noted,
however, that these solutions are extremely unstable 
given the low number of subjects.
Discussion
This study confirmed that TD was significantly related to
a worsening of mood in SSRI-treated, remitted depressed
patients. In view of a number of recent negative studies
(Aberg-Wistedt et al. 1998; Moore et al. 1998), this rep-
lication is relevant. Furthermore, TD was associated with
an increase in anxiety and somatic symptoms, but not
with increase in anger. One patient who was on venlafax-
ine, which is active at both the serotonergic and nor-
adrenergic system, responded to TD. This result is of
note because responders to the noradrenergic antidepres-
sant desipramine are not vulnerable to relapse after TD
(Delgado et al. 1999).
The substantial reduction of Trp levels that were ob-
tained in the control session was unexpected and unintend-
ed, but has some important implications. Despite a 43% re-
duction of Trp levels, no behavioral effects occurred during
the control session. This serendipitous finding is important
in the light of the negative or partly negative findings men-
tioned above (Bremner et al. 1997; Aberg-Wistedt et al.
1998; Moore et al. 1998). Lack of effect in these studies
may well be due to insufficient depletion of tryptophan,
since the level of Trp reduction that was obtained (57.5%,
44.6%, and 52%, respectively) hardly exceeds the reduc-
tion during the control session in the present study. The
present data, combined with those of previous studies (see
Van der Does 2000b), provide some evidence that the
dose-response curve of TD is not linear, and that a thresh-
old exists that needs to be exceeded before behavioral ef-
fects occur. In view of the fact that the body has compensa-
tory reactions to many changes, it may come as no surprise
that the reduction of tryptophan needs to be substantial be-
fore behavioral effects are measurable.
Except for “magnitude of Trp reduction”, the present
study did not identify new predictors or mediators of the
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Biochemical effects of TD and the control procedure
Table 2 shows that the TD procedure was successful in
markedly lowering the ratio Trp/LNAA (82% reduction).
However, due to an unexpected large reduction of Trp
levels in the control condition, not all differences be-
tween the two conditions were significant. As can be
seen in Table 1, one subject even showed a higher reduc-
tion in the control than in the TD session. All data were
re-checked, but no coding errors were detected.
Behavioral effects of TD and the control procedure
Tables 1 and 3 summarize the behavioral effects of both
challenges. The increase in scores on the HRSD-6,
HRSA, SQ Anxiety, and SQ Somatic Symptoms was sig-
nificantly higher during TD than during the control chal-
lenge. Patients therefore reported during the TD session
a significant emergence of depression, anxiety, and so-
matic symptoms compared to the control session, but not
more anger.
Predictors of the effect of TD
Although more patients with a history of true drug re-
sponse pattern to the SSRIs fulfilled the definition of re-
sponder to TD (five out of seven: 71%) than patients
with a placebo response pattern (one out of three: 33%),
this difference failed to reach statistical significance
[χ2(1)=1.3, P=0.26]. All correlations among residualized
change scores (of changes in depression and biochemical
measures) were non-significant. The same held true for
the correlations between symptom changes and duration
of remission and number of episodes.
Fig. 1 Plot of behavioral and biochemical changes during both
challenges. Note: each patient appears twice in this plot. HDRS-6
Six-item Hamilton Depression Rating Scale, TD tryptophan deple-
tion, TRP/LNAA tryptophan/large neutral amino acid
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effects of TD on mood. An important limitation of the
study is the small sample size. However, duration of re-
mission and number of episodes do not emerge from this
study as promising candidates. This does not hold true
for history of response pattern to antidepressant medica-
tion. Although the trend was far from significant, this
variable deserves further investigation. In summary, this
study confirms the mood-lowering effects of TD in a
subgroup of SSRI-treated, formerly depressed individu-
als. Recent negative findings may have been caused by
insufficient lowering of Trp levels.
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